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Introduction
Breast cancer (BC) incidence is increasing sharply in countries in economic transition with a large number of cases in premenopausal women. In Latin America (LA), the frequency of BC in women younger than 45 years is close to twice the frequency seen in developed countries, an increase only partly explained by population age-structure [1] . Behavioural, reproductive and lifestyle factors typical of the Western populations are becoming more prevalent in LA and may play a role in the increased BC incidence in this population, but the reason for the sharp increase in premenopausal women remains to be established [2] .
BC is a heterogeneous disease in terms of biology and outcome. It is clinically classified into four subtypes (Luminal A, Luminal B, HER2 positive, Triple-negative) based on the expression of the oestrogen receptor (ER), progesterone receptor (PR), HER2 receptor and the proliferation marker Ki67 [3] . More sophisticated classifications based on genomic and transcriptional analyses provide a better description of the tumor biology and outcome [4, 5] . The two most frequently somatically mutated genes in BC are TP53 and PIK3CA. Mutations in PIK3CA, which renders cells dependent on PI3K pathway signalling, are the most common genetic abnormality identified in hormone receptor positive breast cancer, while mutations in the tumour suppressor gene TP53 are more prevalent in HER2-enriched and triple-negative (TN) subtypes.
Genomic analyses can also provide information related to tumor aetiology. Indeed, somatic mutational signatures can reveal the contribution of specific mutational processes to the development of cancer. For example, TP53 mutation patterns specific to exposure to exogenous mutagens have been reported in several cancer types [6] , and at the genome-wide level, over 30 mutational signatures have been described in cancer tissues and some have been linked to endogenous mechanisms of mutagenesis or to exposure to human carcinogens [7, 8] .
While BC genomic subtypes have been associated with different patient outcomes, how specific genomic alterations relate to risk factors or aetiology remains largely unknown. Moreover, knowledge of the genomic features of premenopausal BC, particularly in countries in economic transition, is limited. The PRECAMA study was initiated to investigate the molecular, pathological, and risk factor patterns of premenopausal BC in LA (http://precama.iarc.fr/). It is the largest casecontrol study conducted in four Latin American countries that systematically collects both, extensive information on life-style and risk factors, and different biological samples (tumor tissues, blood fractions and urines) according to standardized procedures. PRECAMA is thus a powerful framework for investigating relationships between BC tumor biology and aetiology.
Here, we investigate the tumor genomic features of premenopausal BC (preBC) in Latin American women using the first set of samples collected within the framework of the PRECAMA study.
Materials and Methods

Study population
Subjects were women age 20-45 years diagnosed with BC as part of the PRECAMA casecontrol study (http://precama.iarc.fr). Recruitment was conducted at major general or cancer dedicated hospitals in Chile, Colombia, Costa Rica and Mexico which cover populations with a wide range of socio-economic status. Women having a positive biopsy for BC were recruited prior to any treatment. Women were invited to a home or hospital visit during which a trained nurse presented the informed consent, collected biological samples and anthropometric measurements (height, weight, hip and waist circumferences) and administered a standardized questionnaire on clinical, reproductive, and life-style risk-factors. All participants gave written informed consent before enrolment, and the study protocols were approved by the institutional review boards of Chile (Oncologic Institute 
Biological specimens
Each study site applied common standardized protocols for specimen collection. Protocols have previously been developed and extensively used by IARC [9, 10] , and subsequently fine-tuned based on a detailed review of the conditions at each center. Blood samples were obtained by venipuncture using vacutainers at recruitment and buffy coats were prepared and stored at -80°C within less than 6 hours after blood drawn. Buffy coats were shipped to IARC for genomic DNA extraction. Tumor samples were fixed in formalin and paraffin-embedded (FFPE) according to SOPs. Paraffin blocks and H&E sections were stored at the local pathology service facilities.
Sections from tumor tissues were sent to Fred Hutchinson Cancer Research Center (FHCRC) for centralized immunohistochemistry (IHC) analyses and tumor DNA extraction.
Pathology Review and IHC analyses
Histology sections from tumor biopsy obtained prior to any treatment were reviewed for histological diagnosis and grade, lympho-vascular invasion and stromal and lymphocyte response.
IHC was conducted for ER (SP1, LabVision, Fremont CA), PR (PgR 636, DAKO, Denmark), HER2 (AO485, DAKO, Denmark), EGFR (31G7 Invitrogen, Camarillo CA), CK5/6 (D5/16 B4, DAKO, Denmark), p53 (Pab 1801, Calbiochem, La Jolla CA), Ki-67 (MIB-1, DAKO, Denmark) according to standardized and optimized protocols that included antigen retrieval when required. BCs were classified into subtypes according to ER, PR and HER2 IHC results. Triple negative (ER-, PR-, HER2-) were additionally subtyped using EGFR and CK5/6 staining to define basal-like cancers. ER and PR positivity were defined as staining score >1%, and Ki67 positivity as staining >14% as recommended by the St Gallen International Breast Cancer Conference [3] .
DNA extraction and sequencing
Tumor genomic DNA was extracted from 3 to 9 sections of 6um using the QIAamp DNA FFPE Tissue Kit (Qiagen) following manufacturer's recommended protocol, with the following modification.
The tissue was incubated in ATL buffer and proteinase K overnight at 56°C with agitation, with an additional 20 uL of proteinase K addition after the first four hours. Constitutive genomic DNA was isolated from buffy coats at IARC with the Autopure LS system (Qiagen) using the "frozen buffy coat" protocol and following manufacturer instructions. DNA was quantified by PicoGreen® (ThermoFisher Scientific). 
Bioinformatic analyses
Data from the Ion Proton were processed with the Ion Torrent built-in pipeline (TorrentSuite V4) to generate BAM files and variant calling was done with the built-in ITVC in the somatic mode and with a minimum allelic frequency threshold of 4%. Variants were annotated with Annovar and filtered to eliminate known SNPs (variants present in ExAC or 1000G databases at frequency >0.001) and sequencing artefacts using our MutSpec Galaxy package developed in-house [11] .
Further manual checks of BAM files using IGV were done when appropriate. All non-synonymous mutations found in the targeted regions and present in both duplicates of tumor samples but not in any blood sample were retained for analysis.
Exome data from the HiSeq4000 were analysed with a pipeline developed in-house and based on standards tools for quality control and processing (FastQC 0.11.3, AdapterRemoval 2.1.7, BWA-MEM 0.7.15, Qualimap 2, GATK 3.5, Picard 1.131). Somatic variant calling was done on tumorblood sample pairs with Strelka [12] using default parameters. Variant annotation and filtering was done as described above with MutSpec [11] and only somatic indels and SNVs in coding regions were retained and analysed. Pathway analysis of mutated genes was done with ConsensusPathDB (r32) using KEGG, Biocarta, Reactome and Wikipathways databases and a minimum of 3 overlapping genes and q-value <0.05 as settings [13] . To define cancer genes, we used COSMIC Cancer Gene Census (v82) [14] , and genes identified as drivers in breast cancer in the IntOGen database (r2014.12) [15] .
Public data on somatic mutations in breast cancer
Data from TCGA breast and METABRIC genomic studies [16, 17] and from the IARC TP53
Database [18] were used as comparison datasets. Gene-specific mutation files (AKT1, CDH1, ERBB2, NOTCH1, PIK3CA, PTEN, RB1, TP53 genes) and related clinical files for TCGA and METABRIC studies were retrieved from cBioportal [19, 20] 
Statistical analyses
For mutational signatures analyses, we used PRECAMA exome data (N= 12 samples) and were then extracted using the non-negative matrix factorization (NMF) algorithm implemented in the NMF R package [8, 21] . NMF decomposition identifies signatures and estimates their contributions to each sample. Six signatures were identified using the cophenetic correlation coefficient [20] as a measure of stability of the signatures. We calculated, the cosine similarity between the six extracted signatures and those published in the Catalogue of Somatic Mutations in Cancer (COSMIC) and in other original reports [21, 26, 27] , as described elsewhere [21] .
We 
Results
IHC subtypes in PRECAMA tumors
In the first consecutive cases recruited in PRECAMA and for which tumor pathological evaluation has been completed (N=229), most BC cases were ER positive (72%) and 16% were positive for HER2 ( Table 1) . Using ER/PR/HER2 IHC subtyping, the majority of cases were Luminal A (58%), followed by TN (21), Luminal B (11%) and HER2 enriched-enriched (5%) ( Table 1) . The HER2+ rate overall was 16%. TN tumors were predominately basal-like (98%) (S1 Table) .
Proliferation status was assessed by Ki67 IHC. More than 80% (189/233) of cases had high Ki67 staining (staining >= 14%) with a median percentage of 31.6 (not shown). Ki67 positive cases were less frequent among Luminal A cases than other subtypes (71.6% compared to 88-95%). Potentially deleterious somatic mutations (affecting splicing, indels, nonsense, stoploss, and nonsynonymous substitutions) in the 8-gene panel were found in 63.5% (80/126) of samples. TP53 was the most frequently mutated gene (32.5%), followed by PIK3CA (21.4%) and AKT1 (9.5%), while other genes were mutated in less than 5% of samples. Overall, this distribution was similar to the one obtained in preBC women from TCGA/METABRIC datasets (top mutated genes are TP53 and PIK3CA), although the prevalence of TP53, PIK3CA, AKT1 and RB1 genes mutation prevalence were significantly different (Fig 1A) . There were fewer cases with TP53 and PIK3CA mutations and more cases with AKT1 and RB1 mutations (p<0.05). These differences may be explained in part by the lower proportion of TN and HER2-enriched cases (known to carry TP53 and both TP53 and PIK3CA mutations respectively [22] ) and higher proportion of Luminal A cases (known to carry AKT1 or PIK3CA mutations [22] ) in PRECAMA samples compared to the TCGA/METABRIC datasets (see S1 Fig) . Nonetheless, the relative proportion of PIK3CA versus AKT1 mutations in Luminal A cases was different between PRECAMA and TCGA/METABRIC datasets, with a higher proportion of AKT1 mutated cases in PRECAMA versus TCGA/METABRIC (14% AKT1 and 23%
PIK3CA mutations vs 4% AKT1 and 54% PIK3CA mutations, respectively, although this was not statistically significant). Thus, while the PIK3CA/AKT1 pathway is mutated at expected rates in the Luminal A PRECAMA tumors, AKT1 mutations may be favoured over PIK3CA mutations compared to other published sets, a result that will need to be confirmed in a larger sample set. PIK3CA and AKT1 mutations were at classical hotspots (p.H1047R, p.E542K, p.E545K for PIK3CA and p.E17K
for AKT1), and TP53 mutations were mostly missense substitutions that spread across the coding sequence (S1 Table) . The relationship between IHC subtypes and mutated genes was as expected from previous studies (Fig 1B) . TP53 Table) , we identified 2634 somatic mutations in coding regions, including 2128 non-synonymous SNVs and indels (see S3 Table) . All mutations found by targeted sequencing in the 8-gene panel were confirmed in the exome analysis. There was an average of 3.9 non-synonymous SNVs and indels per MB, with 2 samples carrying more than 6 mutations per MB (Fig 2A, top panel) . The top mutated genes included four cancer genes (TP53, RB1, PIK3CA and AHNAK) and several large sized genes such as mucin genes and TTN gene (Fig 2A, middle panels) . AHNAK has recently been described as a novel tumor suppressor gene in breast cancer, especially in TN subtype, acting via different signaling pathways such as AKT/MAPK or TGFβ [23, 24] . AHNAK, like RB1 mutations were all in TN cases. However, the impact of AHNAK mutations on protein function is unknown as AHNAK is a large size gene and 3/4 of the mutations were predicted as benign by Polyphen-2 [25] .
In TN cases (N=10), there were 92 cancer genes mutated, dominated by TP53 which was mutated in all samples, and with 14 other cancer genes mutated in more than one sample (Fig 2B) . Pathway enrichment analysis of potential driver mutations in these TN samples (S4 Table) showed enrichment for several growth factor signaling pathways and for pathways involved in insulin receptor signaling, telomere maintenance, transmembrane transport of small molecules, G1 checkpoint or O-glycan biosynthesis (Fig 2C and S5 Table) .
Mutation patterns and signatures in premenopausal BC
To study the underlying mutational processes involved in the development of preBC tumors in the studied populations, we analyzed somatic mutation patterns in the TP53 gene and at the exome-wide level. As shown in Fig 3A, the distribution of TP53 mutation substitution types in PRECAMA samples was different from the one observed in other datasets of women younger than 45 years. There was in particular a higher proportion of G:C>T:A mutations in PRECAMA samples compared to BC tumors from young women from the IARC TP53 Database (p-value = 0.004; Chisquare test) or TCGA/METABRIC (p-value = 0.05; Chi-square test) datasets. In fact, G:C>T:A was the most frequent type followed by indels, while G:C>A:T at CpG was the most frequent type in the other datasets. TP53 G:C>T:A mutations were observed in all subtypes while indels were more frequent in TN cases (Fig 3B) . TP53 indels were truncating mutations (predicted to result in loss of p53 protein expression) in 6/10 cases, and 5/6 of these truncating mutations were indeed associated with null p53 IHC staining (see S1 Table) . Thus, while the presence of frequent TP53 truncating mutations in TN subtype was similar to previous reports [26] , the overall high frequency of G:C>T:A mutations was unexpected.
Mutational signatures at the exome-wide level were analysed using a dataset including the 12 PRECAMA samples and 453 BC samples from TCGA (see Materials and Methods). We identified 6 signatures that matched with previously reported signatures (Fig 4A and S6 Table) . The estimated contribution of each signature to the mutation load in PRECAMA samples (Fig 4B) showed that 5/6 signatures had a contribution above 20% in at least one sample. [29, 30] , COSMIC signature-11 observed in recurrent brain tumors of patients treated with MNNG [31] , and COSMIC signature-30 of unknown origin but previously observed in some BC. Sig.D, that matched with COSMIC signature-18, was mainly observed in one sample where it contributed to 90% of the mutation load and where the overall mutation load was the highest. The origin of this signature in BC remains to be established but it has recently been associated with germline mutation in the repair enzyme MUTYH in colorectal and adrenocortical carcinomas [32, 33] . Interestingly, the sample in which Sig.D dominated carried a truncating somatic mutation in MUTYH (see S1 Table) .
Finally, Sig.E, characterized by C>T mutations at CpG site and matching with COSMIC signature-1 known to be due to spontaneous deamination of 5-methylcytosine (also referred as the "age" signature), had significant contribution in only 3 samples.
In Fig 4C, we explored possible systematic differences of signature contributions between IHC subtypes, and by menopausal status or study source (TCGA vs PRECAMA). Sig.F that matched with COSMIC signature-2 and COSMIC signature-13, linked to mutagenesis by APOBEC, was more prevalent in HER2-enriched subtype cases and underrepresented in TN cases (p-value < 5E-4), as reported before [34] . This fits with the fact that we do not find a significant contribution of APOBEC signature in the PRECAMA samples (median contribution of 2.9%) as we only analysed
TN and Luminal A cases. COSMIC signature-3 (Sig.A) was enriched in TN cases (p-value < 5E-4)
and preBC (p-value = 0.03). This signature was the predominant one in PRECAMA TN cases (median contribution of 26.8%). The contribution of the "age" signature (Sig.E) was lower in TN cases than in all other subtypes (p-value < 5E-4) and also lower in preBC compared to postBC (pvalue = 0.006). It was the lowest in PRECAMA samples. The contribution of Sig.D was slightly higher in TN cases compared to all other subtypes (p-value = 0.01) and was the main contributor to the mutation load in one PRECAMA sample (Fig 4B) . As this sample carried a somatic mutation in MUTYH, and a recent study found germline mutations in MUTYH in young women with breast cancer [35] , it will be interesting to further study the role of MUTYH alteration in TN and premenopausal BC. In stratified analyses by IHC subtypes, signatures' contributions in PRECAMA TN cases were similar to the ones observed in TCGA TN samples except for Sig.C (contribution was higher in PRECAMA than in TCGA TN samples, p-value = 0.006, median contributions: 18.6% vs 10.4%). Because Sig.C matched with several signatures, including signatures linked to exposure to alkylating agents not expected in these treatment naïve samples, its origin remains to be established. There was no effect of menopausal status on signature's contributions when taking into account IHC subtype using linear models (all p-values > 0.16; permutation tests of linear regression model).
Discussion
The results obtained in this pilot phase of the PRECAMA study demonstrate feasability regarding advanced genomic analyses of the tumor and blood samples collected at multiple sites in LA. They provide a preview of the molecular features of preBC in that population, with interesting mutational patterns that deserve further study.
Indeed, over 92% of samples processed for IHC analyses were successfully scored for 7 markers (only 20/253 were excluded due to absence of invasive tumor or to insufficient tissue for testing), and 80% of samples processed for DNA extraction yielded DNA quantities and quality compatible with genomic analyses (136/172 samples yielded more than 200 ng of DNA). With a target of 1500 cases recruited for the full study (with Guatemala and Brazil joining the study), this will be the largest series of preBC in LA women where genomic characterization of the tumor will be performed.
The IHC analyses showed a majority of ER positive cases and a proportion of TN subtype similar to previous reports in Hispanic women [36] . The overall prevalence of ER negative tumors in PRECAMA was substantiated by sequencing results on the 8-genes panel analyzed here. Indeed, TP53 mutations, that are strongly associated with ER negative status [37, 38] , were found in 32% of the cases, fitting with an overall 28% of ER negative cases. Also, the frequency of AKT1 mutations, typical of ER positive cases [17, 39] , was higher in PRECAMA than in the comparative dataset of young women. Continued enrollment will allow us to determine more precise estimates of subtype distribution in the LA population and to explore potential differences in tumor subtype distributions between countries.
Although overall tumor characteristics were more similar to those described in postBC than preBC, IHC staining with Ki67 showed high levels of staining in these preBC, even in Luminal A cases (72% positive cases), which is consistent with previous reports on preBC [40, 41] . Liao et al,.
2015 [42] , recently compared the molecular features of preBC versus postBC from TCGA and METABRIC datasets using multi-omic data integration. They reported no difference in gene expression between preBC and postBC in ER negative cases but significant differences in ER positive cases, with activation of integrin signaling and EGFR pathways and TGFβ as the top upstream regulator in preBC. It would thus be important in future studies to assess whether activation of these pathways drives the level of proliferation reflected by high Ki67 positivity in ER positive preBC as they may be potential clinical targets.
The characteristics of the mutations found by target sequencing of the 8-gene panel was similar to the ones observed in other series of BC, with classical hotpots found in AKT1 and PIK3CA, a majority of missense mutations found in TP53, a higher proportion of truncating TP53 mutations in TN cases compared to other subtypes, and an expected distribution of mutated genes within IHC subtypes. However, an interesting difference in the distribution of TP53 single base substitutions was observed. The most frequent TP53 mutation type was G:C>T:A that represented 27% of all TP53 mutations, a figure close to twice the one observed in the comparative datasets used here, and that matches those reported in lung cancers linked to PAH exposure [43, 44] . This pattern is thus unexpected in breast cancer. These G:C>T:A mutations do not exhibit a strand bias, do not cluster at any hotspot, and seemed similarly distributed within IHC subtypes or country of origin, although numbers are still too low to draw any conclusion. As these results may suggest a specific, yet unknown, mutational process at the origin of TP53 mutations, it will be important to confirm them in the full study.
Exome-wide mutation profiling of a subset of basal-like TN tumors confirmed that TP53 and RB1 were the only cancer genes recurrently affected by deleterious mutations (>2 samples). These results are concordant with previous reports on TNBC of basal-like type that showed predominance of TP53 mutations and of TP53 and RB1 pathways alterations [39, 45] . These reports also suggest activation of the PIK3CA/AKT pathway based on gene copy number analyses (PIK3CA gene amplification, PTEN gene deletion) and protein phosphorylation assays [39] . Here we found one activating PIK3CA mutation in 10 TNBC samples, which is in the range of previous reports (9%).
However, as we limited our analyses to SNVs and small indels, we could not further assess the functionality of the PIK3CA pathway. Pathway analysis of potentially functional mutations across all genes showed enrichment of signal transduction pathways including EGFR, PDGF and IGF1R, and mutational signatures showed a large contribution of DNA repair defects to the mutation load. These overall results on TN cases fit with our previous analyses of another series of TN cases from Mexico where transcriptomics analyses showed an overexpression of growth-promoting signals (including EGFR, PDGFR and PIK3CA), a repression of cell cycle control pathways (TP53, RB1) and a deregulation of DNA-repair pathways [46] . 
Conclusions
This pilot results on PRECAMA tumors gives a preview of the molecular features of premenopausal BC in LA. Although, the overall mutation burden was as expected from data in other populations, mutational patterns observed in TP53 suggested possible differences in mutagenic processes giving rise to these tumors compared to other populations. Further omics analyses of a larger number of PRECAMA cases in the near future will allow investigating relationships between these molecular features and etiological factors. Supporting information S1 File. S1-S6 Tables. S1 Table: Demographics and molecular characteristics of cases analysed by NGS; S2 Table: Whole exome sequencing data metrics; S3 Table: Mutations in coding regions from whole exome sequencing and mutation calling with Strelka; S4 Table: List of mutated genes in TN cases with mutations present at an allele frequency above 20% and predicted to impact protein function (splice, truncating and non-synonymous predicted deleterious/probably deleterious by Polyphen-2) (N=333); S5 Table: Pathway analysis of 333 altered genes in TN samples; S6 Table: Cosine similarity values for the comparisons between each of the 6 extracted signatures and 37 published signatures. 
Figure legends
